NCOG-19. NEUROCOGNITIVE OUTCOMES OF EORTC BRAIN TUMOR GROUP STUDY 26101 PHASE III TRIAL COMPARING THE COMBINATION OF LOMUSTINE AND BEVACIZUMAB WITH LOMUSTINE ALONE IN GLIOBLASTOMA PATIENTS WITH FIRST PROGRESSION

BACKGROUND: Despite prolonged PFS, EORTC study 26101 showed that combined treatment of lomustine (LOM) plus bevacizumab (Bev) does not confer an OS advantage over LOM alone. Here we report in detail the outcomes on neurocognitive functioning (NCF) of these patients. METHODS: NCF using Hopkins Verbal...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Klein, Martin, Reijneveld, Jaap C, Idbaih, Ahmed, Brandes, Alba, Taal, Walter, Clement, Paul M, Domont, Julien, Campone, Mario, Taphoorn, Martin J B, Stupp, Roger, Fabbro, Michel, Rhun, Emilie Le, Dubois, Francois, Weller, Michael, Golfinopoulos, Vassilis, Platten, Michael, Gorlia, Thierry, van den Bent, Martin, Wick, Wolfgang
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2017
Assuntos:
Abstracts
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692842/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.580
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares